Literature DB >> 21573452

Ganglioside gd(2) expression in the human nervous-system and in neuroblastomas - an immunohistochemical study.

G Lammie1, N Cheung, W Gerald, M Rosenblum, C Cordoncardo.   

Abstract

The distribution of the disialoganglioside GD2 in the human nervous system was studied by immunostaining using monoclonal antibodies 3F8 and 3A7. Positive staining was detected throughout the central nervous system, predominantly in neuronal cell bodies and neuropil of the gray matter. The specific localization of reactivity in such structures as cerebellum and hippocampus differs from that of related gangliosides, suggesting that GD2 may have a distinct functional role(s) in the brain, and is not merely a metabolic intermediate. GD2 expression was also analyzed in a series of 39 neuroblastomas. Staining of both primitive neuroblastic and differentiating ganglioneuromatous elements was seen, although some tumor cell heterogeneity was noted. The results have implications for immunotherapy of neuro-blastomas using anti-GD2 antibodies.

Entities:  

Year:  1993        PMID: 21573452     DOI: 10.3892/ijo.3.5.909

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  30 in total

1.  Anti-GD2 Strategy in the Treatment of Neuroblastoma.

Authors:  Richard K Yang; Paul M Sondel
Journal:  Drugs Future       Date:  2010       Impact factor: 0.148

2.  Oncotargets GD2 and GD3 are highly expressed in sarcomas of children, adolescents, and young adults.

Authors:  Konstantin Dobrenkov; Irina Ostrovnaya; Jessie Gu; Irene Y Cheung; Nai-Kong V Cheung
Journal:  Pediatr Blood Cancer       Date:  2016-06-15       Impact factor: 3.167

3.  High-Affinity GD2-Specific CAR T Cells Induce Fatal Encephalitis in a Preclinical Neuroblastoma Model.

Authors:  Sarah A Richman; Selene Nunez-Cruz; Babak Moghimi; Lucy Z Li; Zachary T Gershenson; Zissimos Mourelatos; David M Barrett; Stephan A Grupp; Michael C Milone
Journal:  Cancer Immunol Res       Date:  2017-11-27       Impact factor: 11.151

Review 4.  Anti-GD2 immunotherapy for neuroblastoma.

Authors:  Sameer Sait; Shakeel Modak
Journal:  Expert Rev Anticancer Ther       Date:  2017-08-14       Impact factor: 4.512

Review 5.  Targeted therapies for advanced Ewing sarcoma family of tumors.

Authors:  Yunyun Jiang; Joseph Ludwig; Filip Janku
Journal:  Cancer Treat Rev       Date:  2015-03-27       Impact factor: 12.111

6.  Anti-tumor and immunomodulatory activity of resveratrol in vitro and its potential for combining with cancer immunotherapy.

Authors:  Brenda L Soto; Jacquelyn A Hank; Soesiawati R Darjatmoko; Arthur S Polans; Eric M Yanke; Alexander L Rakhmilevich; Songwon Seo; KyungMann Kim; Ralph A Reisfeld; Stephen D Gillies; Paul M Sondel
Journal:  Int Immunopharmacol       Date:  2011-08-18       Impact factor: 4.932

Review 7.  GD2-targeted immunotherapy and radioimmunotherapy.

Authors:  Konstantin Dobrenkov; Nai-Kong V Cheung
Journal:  Semin Oncol       Date:  2014-07-21       Impact factor: 4.929

8.  Quantitative studies of monoclonal antibody targeting to disialoganglioside GD2 in human brain tumors.

Authors:  E Arbit; N K Cheung; S D Yeh; F Daghighian; J J Zhang; C Cordon-Cardo; K Pentlow; A Canete; R Finn; S M Larson
Journal:  Eur J Nucl Med       Date:  1995-05

Review 9.  Neuroblastoma: developmental biology, cancer genomics and immunotherapy.

Authors:  Nai-Kong V Cheung; Michael A Dyer
Journal:  Nat Rev Cancer       Date:  2013-06       Impact factor: 60.716

10.  A phase I clinical trial of the hu14.18-IL2 (EMD 273063) as a treatment for children with refractory or recurrent neuroblastoma and melanoma: a study of the Children's Oncology Group.

Authors:  Kaci L Osenga; Jacquelyn A Hank; Mark R Albertini; Jacek Gan; Adam G Sternberg; Jens Eickhoff; Robert C Seeger; Katherine K Matthay; C Patrick Reynolds; Clare Twist; Mark Krailo; Peter C Adamson; Ralph A Reisfeld; Stephen D Gillies; Paul M Sondel
Journal:  Clin Cancer Res       Date:  2006-03-15       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.